Cigna Implements Value-Based Contract with Novartis for Heart Drug EntrestoTM
February 08 2016 - 9:35AM
Business Wire
Cigna (NYSE: CI) has entered into an outcomes-based contract
with the pharmaceutical company Novartis for the drug Entresto,
which was approved by the U.S. Food and Drug Administration for the
treatment of heart failure with reduced ejection fraction. The
pay-for-performance agreement ties the financial terms to how well
the drug improves the relative health of Cigna's customers. The
primary metric is reduction in the proportion of customers with
heart failure hospitalizations.
“Competitive drug prices are important, but equally so is
ensuring that customers’ medications are actually working as, or
better than, expected. Outcomes-based contracts require that
prescription medicines perform in the real world at least as well
as they did during clinical trials and are a valuable tool for
improving health and managing costs. When pharmaceutical companies
stand behind the performance of their drugs through these kinds of
contracts, we can deliver the most value to Cigna's customers and
clients for the money they are spending,” said Christopher
Bradbury, senior vice president, integrated clinical and specialty
drug solutions for Cigna Pharmacy Management.
This agreement is effective for Cigna's commercial business.
Entresto is a preferred brand subject to prior authorization
review. The prior authorization process is part of utilization
management to help control prescription drug costs and ensure
coverage of the most appropriate drug therapies.
Customer engagement is also a critical component for delivering
improved financial and clinical outcomes. Cigna's pharmacists and
nurses are involved in providing focused clinical care which
includes monitoring a customer’s medication adherence, side effects
and drug interactions; reviewing lab values and collaborating with
customers’ physicians when adjustments are needed.
About Cigna
Cigna Corporation (NYSE: CI) is a global health service company
dedicated to helping people improve their health, well-being and
sense of security. All products and services are provided
exclusively by or through operating subsidiaries of Cigna
Corporation, including Connecticut General Life Insurance Company,
Cigna Health and Life Insurance Company, Life Insurance Company of
North America and Cigna Life Insurance Company of New York. Such
products and services include an integrated suite of health
services, such as medical, dental, behavioral health, pharmacy,
vision, supplemental benefits, and other related products including
group life, accident and disability insurance. Cigna maintains
sales capability in 30 countries and jurisdictions, and has more
than 90 million customer relationships throughout the world. To
learn more about Cigna®, including links to follow us on Facebook
or Twitter, visit www.cigna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160208005778/en/
Cigna CorporationKaren Eldred,
860-787-7015karen.eldred@cigna.com
Cigna (NYSE:CI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cigna (NYSE:CI)
Historical Stock Chart
From Apr 2023 to Apr 2024